Background
Methods
Patients
Methods
Tissue samples and RNA extraction
qRT-PCR for miRNA measurement
Statistical analysis
Results
Patient characteristics and PTC recurrence
Parameters | Recurrent group (n = 24) | Nonrecurrent group (n = 54) |
P value |
---|---|---|---|
Age (year) | 44.9 ± 22.5 | 46.2 ± 18.9 | 0.792 |
Sex | |||
Male | 5(%) | 13(%) | 0.754 |
Female | 19(%) | 41(%) | |
ASA physical status | |||
I | 8(%) | 20(%) | 0.673 |
II | 11(%) | 27(%) | |
III | 5(%) | 7(%) | |
BMI (kg/m2) | 21.4 ± 4.3 | 20.7 ± 3.8 | 0.473 |
ATA risk | |||
Low | 6 | 28 | 0.030* |
Intermediate | 14 | 24 | |
High | 4 | 2 | |
MSKCC–NY risk | |||
Low | 4 | 11 | 0.017* |
Intermediate | 10 | 36 | |
High | 10 | 7 | |
Primary tumor size (mm) | 29.4 ± 5.4 | 22.3 ± 4.8 | <0.001* |
Lymph node dissection | 15(62.5%) | 37(68.5%) | 0.603 |
RAI postoperatively | 6(25.0%) | 22(40.7%) | 0.181 |
Recurrence place | |||
Locoregional | 22(%) | 47(%) | |
Distant metastasis | 2(%) | 7(%) | 0.713 |
Serum thyroglobulin (ng/mL) | 1.6 ± 1.4 | 1.0 ± 1.3 | 0.071 |
TNM stage | |||
I–II | 13 | 43 | 0.021* |
III–IV | 11 | 11 | |
Extrathyroid extension | |||
Yes | 15 | 17 | 0.010* |
No | 9 | 37 | |
Vascular invasion | |||
Yes | 11 | 18 | 0.292 |
No | 13 | 36 | |
Perineural invasion | |||
Yes | 6 | 7 | 0.188 |
No | 18 | 47 | |
Cervical lymph node metastasis | |||
Yes | 7 | 6 | 0.048* |
No | 17 | 48 | |
Histological subtype | |||
Classic | 19 | 42 | 0.891 |
Follicular | 5 | 12 | |
Multifocal tumors | |||
Yes | 13 | 19 | 0.116 |
No | 11 | 35 | |
Bilateral tumors | |||
Yes | 7 | 16 | 0.967 |
No | 17 | 38 |
Tissue miRNA expressions and PTC recurrence
Univariate | Multivariate | |||
---|---|---|---|---|
Variables | HR(95%CI) |
P value | HR(95%CI) |
P value |
ATA risk | ||||
Low × high | 1.67(0.38–7.64) | 0.389 | ||
Low × intermediate | 0.87(0.29–3.35) | 0.879 | ||
Intermediate × high | 3.34(1.42–6.75) | 0.087 | ||
MSKCC–NY risk | ||||
Low × high | 1.67(0.77–3.98) | 0.196 | ||
Low × intermediate | 2.12(0.78–5.86) | 0.132 | ||
Intermediate × high | 1.45(0.52–3.88) | 0.243 | ||
Primary tumor size | 5.14(3.14–11.64) | 0.009* | 1.54(0.43–7.67) | 0.567 |
TNM stage | ||||
I/II × III/IV | 4.31(2.01–9.87) | 0.011* | 2.68(1.10–6.72) | 0.067 |
Extrathyroid extension | 2.12(0.78–6.81) | 0.021* | 2.53(0.54–12.42) | 0.314 |
Cervical lymph node metastasis | 2.85(0.76–6.12) | 0.107 | ||
miR-21 | 2.01(0.33–5.43) | 0.132 | ||
miR-9 | 1.32(0.54–4.53) | 0.225 | ||
miR-146b | 1.11(0.24–4.13) | 0.682 | ||
miR-220 | 1.13(0.45–4.14) | 0.745 | ||
miR-221 | 1.46(1.20–1.88) | 0.001* | 1.41(1.14–1.95) | 0.007* |
miR-222 | 2.81(1.11–7.21) | 0.021* | 1.86(0.76–5.65) | 0.226 |
Univariate and multiple Cox proportional hazard analysis for PTC recurrence
Relative expressions of miR-221 | |||
---|---|---|---|
Parameters | High (n = 12) | Low (n = 12) |
P value |
Disease-free interval (year) | 1.8 ± 4.7 | 1.3 ± 5.3 | 0.801 |
Thyroglobulin (ng/mL) | 1.5 ± 1.0 | 0.6 ± 0.9 | 0.031* |
Cervical lymph node metastasis | 5/12 | 2/12 | 0.371 |